Table 2. Risk ratio for the association between TP53 status and response to neoadjuvant chemotherapy.

Comparison	Total OR*				Pathological OR				Total CR*				Pathological CR
	N	RR (95%CI)	p value	Ph	N	RR (95%CI)	p value	Ph	N	RR (95%CI)	p value	Ph	N	RR (95%CI)	p value	Ph
All studies	26	1.20 (1.09–1.33)	<0.001	0.292	15	1.37 (1.20–1.57)	<0.001	0.329	15	1.33 (1.15–1.53)	<0.001	0.095	12	1.45 (1.25–1.68)	<0.001	0.391
Treatment
Anthracycline-based	17	1.18 (1.04–1.33)	0.010	0.298	10	1.33 (1.19–1.62)	0.005	0.109	12	1.33 (1.15–1.54)	<0.001	0.031	9	1.45 (1.24–1.69)	<0.001	0.175
Type of measurement
Protein	21	1.06 (0.94–1.20)	0.310	0.796	12	1.22 (1.01–1.48)	0.041	0.637	12	1.15 (0.92–1.43)	0.235	0.209	9	1.32 (1.02–1.69)	0.032	0.659
Gene	8	1.41 (1.20–1.65)	<0.001	0.207	4	1.49 (1.24–1.79)	<0.001	0.089	5	1.46 (1.22–1.75)	<0.001	0.076	4	1.49 (1.24–1.79)	<0.001	0.089

Subgroup analysis was performed when there were at least two studies in each subgroup.

N, number of studies; Ph, p value of Q-test for heterogeneity.

^*For studies using both clinical and pathological responses, we used the pathological response data, but also examined the clinical response data, and found similar results (data not shown).

#One study (Oshima et al. [15]) used both genomic sequencing and DNA microarray analysis for gene measurement; we used genomic sequencing data, but also also examined the DNA microarray data, and found similar results (data not shown).